Can You Really Trust
Your Patient Insights?

What's the Story?

Unreliable respondents are the scourge of consumer panels. Our data shows that cheaters and bots typically represent the majority of commercially available diabetes patient sample. We routinely see them in healthcare provider sample as well.

How can you trust the patients that take part in your diabetes market research?

What percentage are fake? What percentage aren’t even real people?

dQ&A – The Real Deal

dQ&A was designed from the ground up to solve for the problem of cheaters and bots. We built and operate our own representative panel of people with diabetes. It’s the only way to ensure accurate and trustworthy insights. Our community is large, but we know it in great detail and continuously check all responses for quality.

Our panel is >99% trustworthy because of the care we’ve put into curating it:

  • No open enrollment - recruited only from legitimate diabetes communities
  • Continuous screening – every person, every survey
  • Dozens of data points about each person – that all need to make sense
  • Every panel member checked by hand
  • Our diabetes expertise makes it possible to identify cheaters based on the nature and patterns of their responses

Who’s Telling The Truth?

When dQ&A assesses the quality of commercially available consumer panels, the results are frightening. Typically, sample vendors are only 10%-30% reliable for diabetes research - which should make everyone think twice. By contrast, using the exact same methodology, we believe that the dQ&A panel is >99% reliable.

It’s Smart to Be Skeptical

If a market research provider purchases third-party sample to conduct diabetes research, then they are exposing themselves to a significant problem, and it is legitimate to question the authenticity of their insights.

Selected Data

Between 2020 and 2024, dQ&A screened over n=67,000 respondents in the USA and Europe from third party consumer panels. All were supposed to be people with diabetes. We had previously developed an in-depth methodology for identifying fraudulent respondents, which would have led us to reject around 90% of the sample we screened.

SAMPLE STATISTICS FOR THE USA THIRD PARTY PANELS 2023-2024
  • In the USA in 2023 and 2024 we screened n=24,276 respondents.
  • Only 11% were acceptable.
  • The rest didn’t fit requirements, were probably fraudulent, or highly suspicious.
REJECT RATE FOR COMMERCIAL SAMPLE VENDORS
  • Reject rate in the USA and Europe is consistently around 90%.
  • There is evidence of a marginal improvement in quality over time.

Karen

Creative, Up-beat Moderator/Interviewer

"Insights I draw from our amazing panelists influence our client's smart decisions and directly improve life for very people I get to interview! How great is that?!”

Trevor

Mixed-Methods Research Expert. Multiple Published Papers.

"As someone with T1D, I'm grateful our work directly impacts devices and therapies”

Christianne

Data Services Architect. Career Research Guru.

“I have been working with dQ&A for over ten years, 100% focused on diabetes. I so love contributing to those mission-critical decisions.”

Phin

VP, Research Services. Structures big data to drive analysis and insight.

“It's a real privilege to work with data that can make such a significant difference”

Kim

10 Years on the Client Side. Delivers Actionable Insights

“At dQ&A I’m surrounded by seasoned researchers and compassionate individuals, united in our mission to make life better for people living with diabetes”

Phyllisa

Patient Advocate. Manages Content for People With Diabetes

“For the first time in my career, I don't deal with diabetes stigma in the workplace.”

You have Questions. We have Answers.

Despite these charts, it is still possible to obtain truly objective and accurate diabetes insights.
If you need trustable data to inform your business decisions, reach out to us.

Do You Have Questions
About Diabetes Research?

We Have Answers.

This research excerpt is just the tip of the iceberg. dQ&A has decades of experience across the United States, Canada, and Europe. If you drive critical diabetes research decisions in your organization, dQ&A is the diabetes insight partner that can get the answers you need.